There is a medication in nearly every emergency department and operating room that people assume is powerful for one reason: it arrives through a needle. That drug is ketorolac — brand name Toradol — and the assumption that “IV means strong, so more must mean stronger” has quietly driven three decades of overdosing.

It’s an easy mistake to make. Ketorolac is a genuinely excellent analgesic. When it hit the U.S. market in 1989, it was the first injectable NSAID available here, and it was marketed as opioid-level relief without the opioid. Hospitals adopted it faster than almost any analgesic in modern history. The problem is that the dose we settled on has very little to do with how much pain it actually relieves.

Every NSAID has a ceiling

NSAIDs are ceiling drugs. There’s a dose at which the pain relief maxes out, and every milligram above that point buys you no additional analgesia — just additional risk, free of charge. Push past the ceiling and you don’t get a more comfortable patient. You get the same comfort with more stomach lining erosion and more stress on the kidneys.

For ketorolac, the FDA label lists 30 mg IV. The evidence says the ceiling sits far below that.

Two trials that put it to the test

This isn’t a theory somebody sketched on a napkin. In 2017, Motov and colleagues at Maimonides ran a randomized, double-blind trial published in Annals of Emergency Medicine. They enrolled 240 emergency patients with moderate-to-severe acute pain and randomized them to 10, 15, or 30 mg of IV ketorolac — 80 patients per group, each dose drawn up by a study pharmacist into an identical-looking syringe so nobody knew who got what.

At thirty minutes, all three groups had dropped from a baseline pain score around 7.5 to roughly 5. The confidence intervals overlapped almost perfectly. Rescue medication rates were the same. Side-effect rates were the same. Tripling the dose changed nothing you’d want and everything you wouldn’t.

Then, in 2021, Eidinejad and colleagues did something even more convincing: they tested 10, 20, and 30 mg against renal colic — the pain of passing a kidney stone, which is about the angriest, most inflammation-driven pain in all of clinical medicine. If a low dose was going to fold under pressure, this is where it would happen. It didn’t. The doses came out tied again.

Two randomized trials. Two different pain models. The same verdict: somewhere between 10 and 15 milligrams — and nowhere near 30.

Meanwhile, in the real world

Here’s the part that stings. One emergency-department study found ketorolac was given above its ceiling dose in roughly 97% of IV administrations. That’s a single center, so treat the exact number with appropriate caution — but nobody who has actually worked in a hospital finds the pattern surprising. Over-dosing this drug isn’t a rare event. It’s a Tuesday.

And the cost of that habit isn’t hypothetical. The milligrams above the ceiling don’t sit there harmlessly. They convert directly into a higher rate of GI bleeding and more renal stress, particularly in the patients least able to absorb it — the elderly, the volume-depleted, the ones already flirting with a creatinine you don’t love.

Why this matters in my world

In oral and maxillofacial surgery, ketorolac is a workhorse for post-operative pain, and it’s a big part of how we keep patients off opioids after procedures like third-molar extractions. That makes getting the dose right a genuine opioid-sparing win, not a rounding error. The lesson from the data is clean: reach for the lowest effective dose, for the shortest duration. In the OR, less really is more.

One fair caveat I’ll flag myself, because precision matters: the Motov trial only tracked patients for two hours, and ketorolac’s analgesia runs four to six. So these trials nail the peak question — is more milligram more relief? — without fully settling duration. There are also niche situations where you may specifically want anti-inflammatory effect rather than pure analgesia. But for the everyday question of “what dose relieves this patient’s pain,” the ceiling is real and it’s low.

The takeaway

More ketorolac does not buy less pain. It buys more risk at exactly the same relief. Two randomized trials, one of them run against kidney-stone pain, land on the same answer that a plain understanding of NSAID pharmacology predicted all along.

So next time you’re on the receiving end of a Toradol order, it’s a perfectly reasonable thing to ask what dose you’re getting. Then wink. They’ll know.